February 25, 2016
Authored and Edited by Kevin D. Rodkey; Elizabeth D. Ferrill; Lauren J. Dreyer
In Nuance Communications v. ABBYY USA Software House, No. 2014-1629 (Fed. Cir. Feb. 22, 2016), the Federal Circuit affirmed a noninfringement judgment against the patentee, Nuance, for all patents in Nuance’s complaint, even those not tried before the jury.
Nuance sued ABBYY and others for infringement, asserting eight patents in its complaint. As the case progressed, Nuance repeatedly agreed to reduce the number of asserted patents and claims, but only after it got full discovery and claim construction rulings on all of its patents. The goal, Nuance told the district court, was to identify its “best” patents during discovery and then assert only a manageable subset of its “strongest” patents in a single trial. On the recommendation of a special master, the district court adopted Nuance’s proposal to reduce the number of patents to four, but Nuance ultimately chose to assert only three patents at trial. After a jury found that ABBYY did not infringe the three patents at trial, the district court entered final judgment for ABBYY. Later, in ruling on ABBYY’s motion for payment of costs, the district court clarified that the judgment applied to all of Nuance’s patents, including those that were not tried.
The Federal Circuit affirmed the judgment, noting that Nuance repeatedly elected to move forward on fewer patents and fewer claims. Nuance argued that it expressly reserved its right to try the unselected patents at a later time, but the Federal Circuit found Nuance’s “boilerplate reservation of rights” insufficient to overcome the special master’s recommendation and Nuance’s intention to have one trial on a subset of its “best” patents. The Court also rejected Nuance’s argument under In re Katz, 639 F.3d 1303 (Fed. Cir. 2011), that the excluded claims presented unique legal issues and their exclusion violated due process. The Court held that Nuance failed to show that it attempted to protect its due-process rights, because it made no objection or assertion that excluding the claims could deprive it of due process.
Copyright © 2016 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
June 10-12, 2024
San Francisco
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
10th Annual Georgia Asian Pacific American Bar Association Gala
May 29, 2024
Atlanta
Webinar
Obviousness of Biologics Inventions: Strategies for Biologics Claims in the U.S., Europe, and China
May 28,2024
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.